About Nybo Therapeutics
Nybo Therapeutics, a subsidiary of PureTech Health (LSE: PRTC), is developing first-in-class immuno-oncology programs dedicated to the targeting of immune-suppressive gamma delta T cells and other related mechanisms in pancreatic cancer and other solid tumors. It aims to address the great unmet need in malignancies with dismal prognoses that derive little benefit from current standards of care.
